Bioventus Inc. Class A Common Stock (BVS) is a publicly traded Healthcare sector company. As of May 21, 2026, BVS trades at $10.92 with a market cap of $720.16M and a P/E ratio of 25.49. BVS moved +2.44% today. Year to date, BVS is +44.52%; over the trailing twelve months it is +56.51%. Its 52-week range spans $5.81 to $14.38. Analyst consensus is strong buy with an average price target of $14.33. Rallies surfaces BVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BVS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BVS recently traded at $10.92. Market cap is $720.16M. P/E ratio is 25.49. Revenue is $576.30M.
| Metric | Value |
|---|---|
| Price | $10.92 |
| Market Cap | $720.16M |
| P/E Ratio | 25.49 |
| EPS | $0.43 |
| Dividend Yield | 0.61% |
| 52-Week High | $14.38 |
| 52-Week Low | $5.81 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $576.30M |
| Net Income | $34.54M |
| Gross Margin | 68.69% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $568.09M | $27.27M | $0.34 |
| 2024 | $573.28M | $-43.83M | $-0.52 |
| 2023 | $512.35M | $-195.63M | $-2.49 |
| 2022 | $512.12M | $-213.39M | $-2.59 |
4 analysts cover BVS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.33.